9:05 AM ET
8-K
Licensing Deal
Recursion Pharmaceuticals Licensing Deal with Tempus AI, Inc. Worth $12M
Recursion Pharmaceuticals granted Tempus AI a non-exclusive license to its TxFM RNA sequencing model for use in oncology in exchange for a $12 million license fee. Simultaneously, the parties amended an existing master agreement to extend its term to six years and restructure annual license fees, while Recursion gained access to additional de-identified pathology records.
- Value
- $12M
- Counterparty
- Tempus AI, Inc.
- Term
- 2 years